Mene Pangalos, AstraZeneca EVP, BioPharmaceuticals R&D (via YouTube)
June 16, 2023 06:00 AM EDT
Deals
Bioregnum
China

As­traZeneca en­lists an up­start Chi­na biotech part­ner in the wake of an R&D set­back

John Carroll

Editor & Founder

One of the new­ly cre­at­ed biotech up­starts in Chi­na has tied up with a Big Phar­ma backer on a dis­cov­ery deal tar­get­ed at hy­per­c­ho­les­terolemia and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times